OOIR: Observatory of International Research

Papers

(The TQCC of Hematological Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Cutaneous T‐cell lymphomas—An update 2021	46
Langerhans cell histiocytosis: Version 2021	34
Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR‐5195‐3p/GRB10 axis	33
Bispecific antibodies for the treatment of lymphomas: Promises and challenges	26
Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies	25
Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B‐cell lymphoma	25
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials	24
Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019	23
Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas	23
A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma	22
FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS	20
Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience	19
Hsa_circ_0002483 regulates miR‐758‐3p/MYC axis to promote acute myeloid leukemia progression	18
SARS‐CoV‐2 vaccine response in CAR T‐cell therapy recipients: A systematic review and preliminary observations	18
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study	18
Low‐dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource‐constrained setting	18
INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL	17
Obinutuzumab‐related adverse events: A systematic review and meta‐analysis	17
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY	17
Immunomodulatory treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)	16
The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors	16
Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature	16
COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients	16
Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B‐cell lymphoma	14
Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide	14

Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity	14
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/	14
The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma	13
Downregulation of circ_0012152 inhibits proliferation and induces apoptosis in acute myeloid leukemia cells through the miR‐625‐5p/SOX12 axis	13
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis	13
High mortality in fully vaccinated hematologic patients treated with anti‐CD20 antibodies during the “Omicron wave” of COVID‐19 pandemic	13
EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL	13
THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS	13
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy	12
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐	12
Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels	12
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma pat	12
Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study	12
Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection	12
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia	11
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience	11
Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study	10
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant	10
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3	10
GENETIC SUBTYPE GUIDED RITUXIMAB‐BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDY	10
Optimizing CAR T cell therapy in lymphoma	10
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia	10
Salvage therapy with “Dara‐KDT‐P(A)CE” in heavily pretreated, high‐risk, proliferative, relapsed/refractory multiple myeloma	10
Mantle cell lymphoma—Advances in molecular biology, prognostication and treatment approaches	10
Bendamustine‐rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients	10
On point in primary CNS lymphoma	10
Seroconversion and kinetic of anti SARS‐COV‐2 antibodies in 25 patients with hematological malignancies who recovered from SARS‐COV‐2 infection	9
Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T‐cell leukemia/lymphoma	9
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients	9
BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL	9
KT‐413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE‐AGENT AND COMBINATION REGRESSIONS IN MYD88^MT LYMPHOMA MODELS	9
Prognostic significance of histologic grade and Ki‐67 proliferation index in follicular lymphoma	9
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches	9
Prognostic significance of IKZF1 deletions and IKZF1^plus profile in children with B‐cell precursor acute lymphoblastic leukemia treated according to the ALL‐IC BFM 2009 protocol	9
Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and	9
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience	9
Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedull	9
Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1	8
GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION	8
The role of long non‐coding RNAs and downstream signaling pathways in leukemia progression	8
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations	8
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report	8
Early serum TARC reduction predicts prognosis in advanced‐stage Hodgkin lymphoma patients treated with a PET‐adapted strategy	8
PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY	8
Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta‐analysis	8
IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL	8
Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients	8
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a	8
CAR T‐cell therapy in large B cell lymphoma	8
Association of Epstein–Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency‐associated lymphoproliferative disorders in pati	8

Allogeneic stem cell transplant in non‐Hodgkin lymphomas: Still an indication?	8
Sinonasal B‐cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B‐cell lymphoma	8
Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: A systematic review and meta‐analysis	8
Direct oral anticoagulants in patients with hematologic malignancies	8
Clinical potential of introducing next‐generation sequencing in patients at relapse of acute myeloid leukemia	8
Safe and effective treatment of follicular lymphoma in patients with HCV‐infection	7
Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma	7
Prognostic value of FDG‐PET/CT response for patient selection before chimeric antigen receptor‐T‐cells therapy in non‐Hodgkin lymphoma	7
Clinical trial risk in leukemia: Biomarkers and trial design	7
Targeted next‐generation sequencing reveals molecular heterogeneity in non‐chronic lymphocytic leukemia clonal B‐cell lymphocytosis	7
Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantation	7
Successful early treatment combining remdesivir with high‐titer convalescent plasma among COVID‐19‐infected hematological patients	7
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY	7
Comparing apples and oranges: The ZUMA‐7, TRANSFORM and BELINDA trials	7
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real‐life experience	7
Pediatric randomized trial EORTC CLG 58951: Outcome for adolescent population with acute lymphoblastic leukemia	7
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients	7
FZD6 triggers Wnt–signalling driven by WNT10B^IVS1 expression and highlights new targets in T‐cell acute lymphoblastic leukemia	7
Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysis	7
Real‐world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The <	7
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia	7
The superiority of Epstein‐Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV‐positive NK‐cell lymphoproliferative diseases	7
LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL	7
Combining T‐cell‐based immunotherapy with venetoclax elicits synergistic cytotoxicity to B‐cell lines in vitro	7
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type	7
GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL	7
TNF‐α increases the risk of bleeding in patients after CAR T‐cell therapy: A bleeding model based on a real‐world study of Chinese CAR T Working Party	7
NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma	7
CD38 expression is an important prognostic marker in diffuse large B‐cell lymphoma	7
Host‐related factors and cancer: Malnutrition and non‐Hodgkin lymphoma	7
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of contr	7
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group	7
Review on natural killer/T‐cell lymphoma	6
Sequencing of myeloma therapy: Finding the right path among many standards	6
DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: Implications for clonal evolution and disease progression	6
Using natural killer cell‐derived exosomes as a cell‐free therapy for leukemia	6
The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor‐based regimens as induction tre	6
Salvage therapy with decitabine in combination with granulocyte colony‐stimulating factor, low‐dose cytarabine, and aclarubicin in patients with refractory or relapsed early T‐cell precursor acute lym	6
Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation	6
SINTILIMAB PLUS CHIDAMIDE FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A PROSPECTIVE, MULTICENTER, SINGLE‐ARM, PHASE IB/II TRIAL (SCENT)	6
The evolving therapy of DLBCL: Bispecific antibodies	6
High inter‐follicular spatial co‐localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma	6
NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY	6
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma	6
FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES	6
Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non‐inferiority, randomized controll	6
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy	6
CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia	6
Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors	6
EPCORITAMAB MONOTHERAPY AND COMBINATIONS IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR RICHTER’S SYNDROME: NEW ESCALATION AND EXPANSION COHORTS IN EPCORE CLL‐1	6
Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre‐CAR T‐cell era	6
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)	6
Implication of immune cell signature of tumor microenvironment in diffuse large B‐cell lymphoma	6
Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluation	6
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826	6
Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial	6
Diagnostic strategy for trigger identification in severe reactive hemophagocytic lymphohistiocytosis: A diagnostic accuracy study	6
Elevated serum IL‐13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B‐cell lymphoma	6
Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper	6
TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)	6
LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	6
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controll	6
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort	6
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection	6
CHARACTERIZATION OF THE GENETIC LANDSCAPE OF HIGH‐GRADE B‐CELL LYMPHOMA, NOS – AN LLMPP PROJECT	6
Extended follow‐up of CD4⁺ T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine	6
CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS	6
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti‐CD19‐chimeric antigen receptor T cells in patients with rela	6
Clinical significance of tryptophan catabolism in follicular lymphoma	5
Critical role of the high mobility group A proteins in hematological malignancies	5
MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES	5
Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group	5
Molecular classification of aggressive lymphomas—past, present, future	5
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents	5
FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI‐CD19 CAR T‐CELL THERAPY	5
Long term outcomes of gastric mucosa‐associated lymphoid tissue lymphoma treated with radiotherapy: A multi‐center retrospective cohort study	5
High prevalence of MEF2D fusion in human B‐cell precursor acute lymphoblastic leukemia cell lines	5
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group	5
Intensified conditioning regimens improved disease‐free survival and engraftment after unrelated single‐unit cord blood transplantation but not after matched sibling or matched unrelated donor allogen	5
High‐grade B‐cell lymphomas with MYC and BCL2 translocations lack tumor‐associated macrophages and PD‐L1 expression: A possible noninflamed subgroup	5

Critical concepts and management recommendations for cutaneous T‐cell lymphoma: A consensus‐based position paper from the Italian Group of Cutaneous Lymphoma	5
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome	5
IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC	5
FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA	5
Are we reaching the maximum cure rate for Hodgkin lymphoma?	5
Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data	5
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	5
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK	5
Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T‐cell precursor acute lymphoblastic leukemia	5
OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL)	5
Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B‐cell lymphoma	5
Prognostic impact of B‐vitamins involved in one‐carbon metabolism in patients with diffuse large B‐cell lymphoma	5
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study	5
The “m6A writer” METTL3 and the “m6A reader” IGF2BP2 regulate cutaneous T‐cell lymphomas progression via CDKN2A	5
Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib	5
TAFRO syndrome: A disease that known is half cured	5
Outcome of therapy‐related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis	5
PRELIMINARY SAFETY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES TREATED WITH THE NOVEL B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB‐11417	4
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective	4
Primary large B‐cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH‐CCND1): Diffuse large B‐cell lymphoma with CCND1	4
Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms	4
Research progress on exosomes derived from mesenchymal stem cells in hematological malignancies	4
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells	4
B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphoma	4
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement	4
Poor survival and prediction of prolonged isolated thrombocytopenia post umbilical cord blood transplantation in patients with hematological malignancies	4
Effects of the BTN162b2 mRNA COVID‐19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia	4
Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patients	4
Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapy	4
UPDATED EFFICACY AND SAFETY RESULTS OF ORELABRUTINIB IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL CELL LEUKEMIA	4
Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leu	4
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia	4
Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis	4
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era	4
Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone	4
FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1‐POSITIVE PERIPHERAL T‐CELL LYMPHOMA	4
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY	4
Autologous hematopoietic cell transplantation versus whole‐brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta‐analysis	4
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY	4
Non‐overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia	4
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis	4
Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis	4
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease	4
Is race important in genomic classification of hematological neoplasms?	4
The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia‐related changes treated with azaciti	4
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review	4
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma	4
Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement	4
Drug cost savings in phase III hematological oncology clinical trials in a university hospital	4
Precision medicine in follicular lymphoma: Focus on predictive biomarkers	4
Immunophenotype of acute lymphoblastic leukemia in minorities‐ analysis from the SEER database	4
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis	4
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland	4
ROLE OF MAINTENANCE RITUXIMAB AFTER FIRST‐LINE BENDAMUSTINE + RITUXIMAB OR R‐CHOP IN PATIENTS WITH MANTLE CELL LYMPHOMA FROM A LARGE US REAL‐WORLD COHORT	4
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation	4
Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies	4
OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDY	4
What's new in peripheral T‐cell lymphomas	4
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R MCL: PRIMARY ANALYSIS RESULTS FROM THE MCL COHORT OF THE SINGLE‐ARM, MULTICENTER, SEAMLESS DESIGN TRANSCEND NHL 001 STUDY	4
Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma	4
Lenalidomide treatment for recurrent adult T‐cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation	4
Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant	4
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE REAL WORLD	4
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)	4
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY	4
Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T‐cell acute lymphoblastic leukemia	4
Upfront identification of high‐risk follicular lymphoma	4
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management	4
Vulnerabilities in the tumor and microenvironment in follicular lymphoma	4
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics	4
PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA	4
Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: A single‐institution experience on 1247 installations in 94 consecutive patien	4
Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia	4
High‐risk follicular lymphoma: Treatment options	4
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia	4
Cellular therapy in lymphoma	4
Novel agents in relapsed/refractory diffuse large B‐cell lymphoma	4
Association of cesarean section with risk of childhood leukemia: A meta‐analysis from an observational study	3
Malnutrition diagnosed by GLIM criteria better predicts long‐term outcomes for patients with non‐Hodgkin's lymphoma: A prospective multicenter cohort study	3
BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FI	3
Prognostic factors of children and adolescents with T‐cell acute lymphoblastic leukemia after allogeneic transplantation	3
CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment	3
SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY	3
Reappraisal of the role of radiation therapy in lymphoma treatment	3
A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE (LONCA) VERSUS (VS) IDELALISIB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) – LOTIS‐6	3
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)	3
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement	3
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)	3
Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system	3
DETERMINANTS OF RESISTANCE TO ENGINEERED T‐CELL THERAPIES TARGETING CD19 IN LYMPHOMA	3
EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA	3
B‐cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non‐Hodgkin's Lymphoma	3
Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospec	3
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myel	3
Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomas	3